Clinical Trial Detail

NCT ID NCT03530696
Title T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Arizona
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Palbociclib

Age Groups: adult senior

Additional content available in CKB BOOST